HepaSphere Interventional Therapy Using Digital Subtraction Angiography（DSA） for Cervical Carcinoma
NCT ID: NCT02523365
Last Updated: 2016-08-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1/PHASE2
60 participants
INTERVENTIONAL
2015-05-31
2016-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Prospective Study of Fertility-sparing Treatment Strategy in Patients With Early Cervical Cancer(SYSUGO-005/CSEM009)
NCT02624531
Screening and Identification of Biomarkers on Cervical Cancers
NCT00854269
Clinical Trial of Minimally Invasive Surgery Versus Abdominal Surgery in Patients With Early Stage Cervical Cancer
NCT03955185
Survival Outcomes of Uterine Cervical Malignancies in Chinese Population
NCT03291236
Usefulness of FDG-PET for Advanced Cervical Cancer
NCT00146458
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
HepaSphere
cervical carcinoma patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）
interventional therapy
cervical carcinoma patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）
control
cervical carcinoma patients received traditional therapy
interventional therapy
cervical carcinoma patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
interventional therapy
cervical carcinoma patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Karnofsky performance status \>60
3. Diagnosis of cervical carcinoma based on histology or the current accepted radiological measures.
4. Classification tumor,nodes,metastasis-classification(TNM) stage: Ⅱ,Ⅲ,Ⅳ
5. Will receive interventional therapy
6. Life expectancy: Greater than 3 months
7. Patients' routine blood test, liver function and kidney function have no obvious abnormalities
8. Ability to understand the study protocol and a willingness to sign a written informed consent document
Exclusion Criteria
2. History of coagulation disorders or anemia
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Fuda Cancer Hospital, Guangzhou
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Lizhi Niu, PhD
Role: STUDY_CHAIR
Fuda Cancer Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Central laboratory in Fuda cancer hospital
Guangzhou, Guangdong, China
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Niu L, Chen J, Yao F, Zhou L, Zhang C, Wen W, Bi X, Hu Y, Piao X, Jiang F, Zeng J, Liu W, Li J, He L, Mu F, Zuo J, Xu K. Percutaneous cryoablation for stage IV lung cancer: a retrospective analysis. Cryobiology. 2013 Oct;67(2):151-5. doi: 10.1016/j.cryobiol.2013.06.005. Epub 2013 Jun 24.
Related Links
Access external resources that provide additional context or updates about the study.
related information
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Cervical Carcinoma HepaSphere
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.